Development of matrix metalloproteinase inhibitors in cancer therapy
- PMID: 11158186
- DOI: 10.1093/jnci/93.3.178
Development of matrix metalloproteinase inhibitors in cancer therapy
Abstract
The matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in the degradation of the extracellular matrix. The MMPs have been implicated in the processes of tumor growth, invasion, and metastasis; are frequently overexpressed in malignant tumors; and have been associated with an aggressive malignant phenotype and adverse prognosis in patients with cancer. A number of MMP inhibitors are being developed for the treatment of cancer. The most extensively studied class of MMP inhibitors includes collagen peptidomimetics and nonpeptidomimetic inhibitors of the MMP active site, tetracycline derivatives, and bisphosphonates. The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail. Marimastat is currently being studied in randomized clinical trials. The nonpeptidic MMP inhibitors were synthesized in an attempt to improve the oral bioavailability and pharmaceutical properties of the peptidic inhibitors. Several members of this class of compounds are undergoing evaluation in phase III clinical trials. The tetracyclines and, particularly, the nonantibiotic chemically modified tetracyclines, interfere with several aspects of MMP expression and activation and inhibit tumor growth and metastases in preclinical models. A representative agent of this class, Col-3, is currently undergoing phase I clinical trials. The development of the MMP inhibitors, like that of other targeted and predominantly antiproliferative compounds, poses a challenge because the paradigms that have governed the design of clinical oncology trials may not be relevant to this new class of agents. The anticipated need for long-term administration of these drugs, together with their cytostatic mechanism of action, will require novel clinical trial design strategies.
Similar articles
-
Matrix metalloproteinase inhibitors.Invest New Drugs. 1997;15(1):61-75. doi: 10.1023/a:1005722729132. Invest New Drugs. 1997. PMID: 9195290 Review.
-
New drugs on the horizon: matrix metalloproteinase inhibitors.Stem Cells. 1999;17(4):237-40. doi: 10.1002/stem.170237. Stem Cells. 1999. PMID: 10437989 No abstract available.
-
[Expression of matrix metalloproteinases in patients with malignant tumors].Medicina (Kaunas). 2004;40(12):1143-50. Medicina (Kaunas). 2004. PMID: 15630339 Review. Lithuanian.
-
MMP inhibitors: experimental and clinical studies.Int J Biol Markers. 1999 Oct-Dec;14(4):232-8. doi: 10.1177/172460089901400406. Int J Biol Markers. 1999. PMID: 10669951 Review.
-
The synthesis and biological activity of a novel series of diazepine MMP inhibitors.Bioorg Med Chem Lett. 1998 Oct 6;8(19):2657-62. doi: 10.1016/s0960-894x(98)00473-9. Bioorg Med Chem Lett. 1998. PMID: 9873598
Cited by
-
Skin Malignant Melanoma and Matrix Metalloproteinases: Promising Links to Efficient Therapies.Int J Mol Sci. 2024 Jul 17;25(14):7804. doi: 10.3390/ijms25147804. Int J Mol Sci. 2024. PMID: 39063046 Free PMC article. Review.
-
Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer.Front Oncol. 2024 Jan 15;13:1325095. doi: 10.3389/fonc.2023.1325095. eCollection 2023. Front Oncol. 2024. PMID: 38288108 Free PMC article. Review.
-
Towards better antivenoms: navigating the road to new types of snakebite envenoming therapies.J Venom Anim Toxins Incl Trop Dis. 2023 Dec 18;29:e20230057. doi: 10.1590/1678-9199-JVATITD-2023-0057. eCollection 2023. J Venom Anim Toxins Incl Trop Dis. 2023. PMID: 38116472 Free PMC article.
-
The Cytotoxic Properties of Extreme Fungi's Bioactive Components-An Updated Metabolic and Omics Overview.Life (Basel). 2023 Jul 25;13(8):1623. doi: 10.3390/life13081623. Life (Basel). 2023. PMID: 37629481 Free PMC article. Review.
-
The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target.Front Immunol. 2023 Mar 13;14:1094823. doi: 10.3389/fimmu.2023.1094823. eCollection 2023. Front Immunol. 2023. PMID: 36993955 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources